Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Depreciation & Amortization (CF) (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Depreciation & Amortization (CF) for 16 consecutive years, with $1.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 8.2% to $1.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.6 million, a 11.21% increase, with the full-year FY2024 number at $4.2 million, up 33.08% from a year prior.
  • Depreciation & Amortization (CF) was $1.2 million for Q3 2025 at Xtant Medical Holdings, down from $1.2 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.2 million in Q2 2025 to a low of $281000.0 in Q1 2022.
  • A 5-year average of $706631.6 and a median of $803000.0 in 2023 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): plummeted 45.26% in 2021, then surged 216.82% in 2023.
  • Xtant Medical Holdings' Depreciation & Amortization (CF) stood at $291000.0 in 2021, then increased by 10.31% to $321000.0 in 2022, then soared by 216.82% to $1.0 million in 2023, then increased by 12.88% to $1.1 million in 2024, then increased by 1.13% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for XTNT's Depreciation & Amortization (CF) are $1.2 million (Q3 2025), $1.2 million (Q2 2025), and $1.1 million (Q1 2025).